Related Experiment Video

Updated: Oct 13, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

[Effect of arotinolol on insulin secretion and insulin clearance rate in patients with Graves' disease]

S Ohguni1, K Notsu, J Tanaka

  • 1Department of Medicine, Shimane Medical University, Izumo, Japan.

Nihon Naibunpi Gakkai Zasshi
|August 20, 1993
PubMed

Insights

Arotinolol treatment in hyperthyroid patients suppressed insulin secretion by reducing insulin clearance rate (ICR). However, it did not affect glucose-induced insulin release or insulin sensitivity.

Area of Science:

  • Endocrinology
  • Metabolic Research

Background:

  • Hyperthyroidism can alter glucose metabolism and insulin dynamics.
  • Understanding the effects of medications on these processes is crucial for patient management.

Purpose of the Study:

  • To investigate the impact of arotinolol on glucose-induced insulin secretion and insulin sensitivity in hyperthyroid Graves' disease patients.

Main Methods:

  • Evaluated five hyperthyroid Graves' disease patients before and after arotinolol treatment.
  • Assessed glucose-induced insulin secretion, 24-h urinary C-peptide (CPR), basal posthepatic insulin delivery rate (BPIDR), glucose infusion rate (GIR), glucose clearance rate (GCR), and insulin clearance rate (ICR) using euglycemic clamp techniques.

Main Results:

  • Arotinolol did not alter plasma glucose or insulin responses to oral glucose.
  • 24-h urinary CPR and BPIDR were significantly suppressed by arotinolol.
  • Insulin clearance rate (ICR) was significantly suppressed.
  • Insulin sensitivity (GIR) and glucose clearance rate (GCR) remained unaffected.

Conclusions:

  • Arotinolol inhibits insulin secretion in hyperthyroid patients primarily by decreasing insulin clearance rate (ICR).
  • Arotinolol does not impair glucose-induced insulin release or affect insulin sensitivity in this patient group.

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...